Quest Diagnostics
818 hedge funds and large institutions have $13.2B invested in Quest Diagnostics in 2024 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 270 increasing their positions, 312 reducing their positions, and 87 closing their positions.
117% more call options, than puts
Call options by funds: $149M | Put options by funds: $68.6M
1.2% more ownership
Funds ownership: 88.54% → 89.74% (+1.2%)
3% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 87
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 826 → 818 (-8)
4% less capital invested
Capital invested by funds: $13.7B → $13.2B (-$510M)
13% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 312
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMI
Fiduciary Management Inc
Milwaukee,
Wisconsin
|
+$194M |
| 2 |
Goldman Sachs
New York
|
+$176M |
| 3 |
8KM
8 Knots Management
Dallas,
Texas
|
+$64.6M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$57.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$54.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$318M |
| 2 |
Morgan Stanley
New York
|
-$244M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$51.7M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$40.2M |
| 5 |
Renaissance Technologies
New York
|
-$37.4M |
DGX Hedge Fund Activity: Q1 2024 in Review
818 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2024, worth a combined $13.2B — down 3.7% from $13.7B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new DGX positions and 87 closed out — a net gain of 3 holders — while 270 added to existing stakes and 312 trimmed.
The largest buyer was Fiduciary Management Inc, opening a new position worth an estimated $194M. The largest seller was T. Rowe Price Associates, cutting an estimated $318M.
- 818 institutional investors held Quest Diagnostics (DGX) as of Q1 2024, down from 826 in Q4 2023.
- Funds reported $13.2B of Quest Diagnostics stock for Q1 2024, down 3.7% quarter-over-quarter.
- 90 funds opened new Quest Diagnostics positions in Q1 2024 and 87 closed out, a net change of +3 holders.
- The largest Quest Diagnostics buyer in Q1 2024 was Fiduciary Management Inc, an estimated $194M added.
- The largest Quest Diagnostics seller in Q1 2024 was T. Rowe Price Associates, an estimated $318M sold.
Based on aggregated 13F filings for Q1 2024.